Earnings summaries and quarterly performance for BICYCLE THERAPEUTICS.
Executive leadership at BICYCLE THERAPEUTICS.
Kevin Lee
Detailed
Chief Executive Officer
CEO
AY
Alethia Young
Detailed
Chief Financial Officer
AM
Alistair Milnes
Detailed
Chief Operating Officer
EW
Eric Westin
Detailed
Chief Medical Officer
JP
Jennifer Perry
Detailed
Chief Strategy Officer and Head of Commercial
MH
Michael Hannay
Detailed
Chief Product and Supply Chain Officer
MS
Michael Skynner
Detailed
Chief Technology Officer
ZQ
Zafar Qadir
Detailed
Chief Legal Officer and General Counsel
Board of directors at BICYCLE THERAPEUTICS.
AR
Alessandro Riva
Detailed
Director
CS
Charles Swanton
Detailed
Director
FB
Felix Baker
Detailed
Non‑Executive Chairman
GW
Gregory Winter
Detailed
Director
HH
Hervé Hoppenot
Detailed
Director
JB
Janice Bourque
Detailed
Director
JG
Jose-Carlos Gutierrez-Ramos
Detailed
Director
RD
Roger Dansey
Detailed
Director
SS
Stephen Sands
Detailed
Director
Research analysts covering BICYCLE THERAPEUTICS.
Recent press releases and 8-K filings for BCYC.
Bicycle Therapeutics Highlights 2025 Accomplishments and 2026 Strategic Priorities
BCYC
Guidance Update
New Projects/Investments
- Bicycle Therapeutics expects its financial runway to extend into 2028 to support its clinical and strategic priorities.
- The company anticipates providing an update on dose selection from the Phase 2/3 Duravelo-2 trial and the potential approval pathway for zelenectide pevedotin in 1Q 2026.
- Initial data for the Phase 1/2 Duravelo-3 trial exploring zelenectide pevedotin in NECTIN4-amplified breast cancer is expected in the second half of 2026.
- Progress in the emerging radiopharmaceuticals pipeline includes plans for additional EphA2 human imaging data in the first half of 2026 and established collaborations for an end-to-end supply chain for 212Pb.
3 days ago
Bicycle Therapeutics Highlights Clinical Progress and Financial Runway
BCYC
Guidance Update
New Projects/Investments
Product Launch
- Bicycle Therapeutics reported cash and cash equivalents of $648.3 million as of September 30, 2025, providing an expected financial runway into 2028.
- The company's lead candidate, zelenectide, a Nectin-4 targeting drug conjugate, demonstrated an Overall Response Rate (ORR) of 45% and a median Duration of Response (mDOR) of 11.1 months in 2L+ EV-naïve metastatic urothelial cancer (mUC) in the Ph1/2 Duravelo-1 study. An update on Duravelo-2 dose selection and potential expedited approval pathways in mUC is anticipated in 1Q 2026.
- Bicycle Therapeutics is advancing its oncology pipeline with BT5528 (EphA2-targeting) and BT7480 (Nectin-4/CD137 targeting), both of which have Phase 1 combination data with nivolumab expected in 1H 2026. Additionally, new EphA2 human imaging data for its radioconjugate pipeline is also expected in 1H 2026.
3 days ago
Bicycle Therapeutics Provides Pipeline and Financial Updates at Jefferies Conference
BCYC
Guidance Update
New Projects/Investments
- Bicycle Therapeutics updated the timeline for dose selection in the pivotal Phase II/III study for zelenectide pevedotin (DV-2) in bladder cancer, now expected in Q1 2026, a slight shift from Q4 2025, to allow for global regulatory feedback.
- The company reported a strong financial position with $648 million in cash as of September, providing a cash runway into Q1 2028.
- Significant updates for BT5528, targeting EphA2, are anticipated at a medical conference in H1 2026.
- Bicycle is also exploring zelenectide's potential in Nectin-4 amplified solid tumors like breast and lung cancer, with studies actively enrolling.
Nov 18, 2025, 10:30 AM
Bicycle Therapeutics Provides Updates on Zelenectide Pevedotin Development and Financial Position
BCYC
Guidance Update
New Projects/Investments
- Bicycle Therapeutics is advancing zelenectide pevedotin, a Nectin-4 targeted MMAE drug conjugate, in a seamless Phase 2/3 pivotal study for bladder cancer, with a dose selection update now expected in Q1 2026 to allow for global regulatory feedback.
- The company reported $648 million in cash as of September, providing a cash runway into Q1 2028.
- Beyond its lead program, Bicycle is developing BT5528 (targeting EphA2) with a significant update anticipated in H1 2026, and is also making significant efforts in radio conjugates.
- Zelenectide pevedotin is also being explored for Nectin-4 amplified tumors, a potential opportunity in breast and lung cancers, with studies actively enrolling.
Nov 18, 2025, 10:30 AM
Bicycle Therapeutics Updates on Zelenectide Pevedotin Development and Financial Position
BCYC
Product Launch
Guidance Update
New Projects/Investments
- Bicycle Therapeutics is advancing its lead molecule, zelenectide pevedotin, a Nectin-4 targeted MMAE drug conjugate, in a pivotal Phase 2/3 study (Duravelo-2) for bladder cancer, aiming for comparable efficacy with a differentiated safety profile compared to Padcev.
- The timeline for dose selection in the Duravelo-2 study for zelenectide pevedotin has been adjusted from Q4 2025 to Q1 2026 to ensure alignment with global regulatory bodies.
- The company reported $648 million in cash as of September, providing a cash runway into Q1 2028, which is sufficient to complete the Duravelo-2 study through Phase 3.
- Bicycle Therapeutics is also progressing BT5528, targeting EphA2, with a significant update expected in H1 2026, and exploring opportunities for zelenectide pevedotin in Nectin-4 amplified solid tumors and in radio conjugates.
Nov 18, 2025, 10:30 AM
Bicycle Therapeutics Reports Q3 2025 Financial Results and Business Progress
BCYC
Earnings
New Projects/Investments
Guidance Update
- Bicycle Therapeutics plc reported cash and cash equivalents of $648.3 million as of September 30, 2025, excluding a $38.2 million U.K. R&D tax credit received in October 2025, and anticipates a financial runway into 2028.
- The company expects to provide an update on dose selection for the Phase 2/3 Duravelo-2 pivotal trial and zelenectide pevedotin's potential approval pathway in metastatic urothelial cancer in the first quarter of 2026, following feedback from multiple regulatory agencies.
- For the three months ended September 30, 2025, the company reported a net loss of $59.1 million, or $(0.85) basic and diluted net loss per share.
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| R&D Expenses ($USD Thousands) | $48,265 | $58,426 |
| G&A Expenses ($USD Thousands) | $18,257 | $18,859 |
| Net Loss ($USD Thousands) | $(50,802) | $(59,100) |
| Net Loss Per Share ($USD) | $(0.74) | $(0.85) |
Oct 30, 2025, 11:05 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more